D86.0

Sarcoidosis of lung

Sarcoidosis of lung (D86.0) is a specific manifestation of sarcoidosis, a systemic granulomatous disease of unknown etiology characterized by the presence of non-caseating granulomas in various organs, most frequently the lungs and intrathoracic lymph nodes. In pulmonary sarcoidosis, these granulomas can lead to inflammation and eventually fibrosis of the lung tissue, impairing gas exchange. The Scadding staging system is often used to categorize the radiographic extent, ranging from Stage I (bilateral hilar lymphadenopathy) to Stage IV (advanced pulmonary fibrosis). While many patients remain asymptomatic or experience spontaneous remission, others develop chronic progressive disease requiring immunosuppressive therapy, typically systemic corticosteroids to prevent irreversible lung damage and respiratory failure.

Clinical Symptoms

Progressive dyspnea on exertion
Persistent dry, non-productive cough
Chest discomfort or retrosternal tightness
Wheezing
General malaise and fatigue
Night sweats
Unexplained weight loss
Exercise intolerance
Subacute chest pain
Hemoptysis (rare, typically associated with secondary aspergilloma)
Crackles or rales on auscultation (rare)

Common Causes

Exaggerated T-cell mediated immune response to unknown antigens
Genetic predisposition involving HLA-DRB1 alleles
Environmental exposure to inorganic dusts or molds
Potential infectious triggers such as Mycobacterium or Propionibacterium species
Dysregulation of Th1-type cytokine profiles (IL-2, IFN-gamma)

Documentation & Coding Tips

Specify the Radiographic Scadding Stage to accurately reflect disease severity and progression.

Example: Patient presents for evaluation of chronic sarcoidosis of the lung, specifically Scadding Stage III with diffuse parenchymal opacities and no hilar lymphadenopathy. History is notable for 5 years of exertional dyspnea. Spirometry reveals a restrictive pattern with a DLCO of 58 percent predicted. This chronic status supports HCC 112 assignment and justifies moderate-complexity MDM for established patient management.

Billing Focus: Documentation of radiographic staging (Stage 0 to IV) and functional impairment levels via PFTs.

Clearly distinguish between lung-only involvement and combined lung and lymph node involvement for code precision.

Example: Diagnostic CT chest confirms isolated parenchymal involvement consistent with sarcoidosis of lung without evidence of intrathoracic lymphadenopathy. Evaluation focused on primary pulmonary sarcoidosis, Stage III. Plan includes continuing oral prednisone 10mg daily for chronic management of this HCC-eligible condition.

Billing Focus: Laterality is not applicable for D86.0, but specific exclusion of lymph nodes is necessary to avoid incorrect bundling with D86.2.

Document secondary complications like pulmonary fibrosis or pulmonary hypertension as distinct diagnoses.

Example: Patient with established sarcoidosis of lung (D86.0) now presenting with secondary pulmonary arterial hypertension (I27.21) and interstitial pulmonary fibrosis (J84.10). Documentation of these manifestations as distinct, linked conditions supports high-complexity MDM and accurate hierarchical risk adjustment.

Billing Focus: Use of 'due to' or 'secondary to' language to establish clinical causal links between the sarcoidosis and its sequelae.

Record the impact on daily activities and the specific treatment response to justify higher E/M levels.

Example: Chronic lung sarcoidosis currently stable on Methotrexate 15mg weekly. Patient reports 6-minute walk test distance of 350 meters, limited by Grade 2 mMRC dyspnea. No acute flares in the last 6 months. Continued monitoring for immunosuppressant toxicity and disease stability for this chronic HCC condition.

Billing Focus: Functional status and medication side-effect monitoring support the complexity of the medical decision making.

Detail biopsy results and histopathological evidence of non-caseating granulomas to confirm diagnosis.

Example: Diagnosis of sarcoidosis of lung confirmed by transbronchial biopsy performed on May 12, showing non-caseating granulomas in the absence of fungal or acid-fast bacilli. Patient currently managed for Stage II disease with active parenchymal involvement. Documentation of pathology supports the clinical validity of the ICD-10 code for audit purposes.

Billing Focus: Reference to diagnostic procedures (CPT 31628) and pathology reports to provide objective evidence for the primary diagnosis.

Relevant CPT Codes

99214 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a moderate level of medical decision making
Typically used for chronic sarcoidosis patients requiring medication adjustments or monitoring of progressive lung disease.
99215 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a high level of medical decision making
Appropriate for patients with severe pulmonary fibrosis, life-threatening flares, or multi-organ sarcoidosis management.
94010 - Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
Standard objective test to monitor the restrictive lung disease characteristic of D86.0.
94726 - Plethysmography for determination of lung volumes and, when performed, airway resistance
Essential for confirming restrictive lung disease when spirometry suggests a reduction in volumes.
94729 - Diffusing capacity of the lungs for carbon monoxide (eg, CO, single breath, DLCO)
Most sensitive PFT parameter for early interstitial lung involvement in sarcoidosis.
71250 - Computed tomography, thorax, without contrast material
Standard imaging modality for identifying parenchymal opacities and staging sarcoidosis (Scadding stages).
31628 - Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe
The gold standard for providing histopathological evidence of sarcoidosis of lung.
31629 - Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), trachea, main bronchus and/or lobar bronchus(i)
Used when hilar lymphadenopathy is present alongside parenchymal disease (often moving the diagnosis to D86.2).
82150 - Amylase; blood
Sometimes used to monitor salivary gland involvement, though ACE levels are more disease-specific.
99213 - Office or other outpatient visit for the evaluation and management of an established patient, which requires a low level of medical decision making
Used for routine follow-up of stable pulmonary sarcoidosis patients not requiring medication changes.